The Cooper Companies, Inc. (NASDAQ:COO – Free Report) – Equities research analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of Cooper Companies in a report issued on Thursday, June 19th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will post earnings per share of $1.06 for the quarter, up from their prior estimate of $1.05. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q4 2025 earnings at $1.11 EPS, FY2025 earnings at $4.05 EPS and Q4 2026 earnings at $1.21 EPS.
COO has been the subject of several other reports. Wells Fargo & Company lowered their target price on Cooper Companies from $118.00 to $93.00 and set an “overweight” rating for the company in a research note on Friday, May 30th. Needham & Company LLC upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research report on Tuesday, June 17th. BNP Paribas upgraded shares of Cooper Companies to a “hold” rating in a report on Thursday, March 13th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $76.00 price target (down previously from $110.00) on shares of Cooper Companies in a research note on Friday, May 30th. Finally, UBS Group upgraded Cooper Companies to a “buy” rating in a report on Tuesday, June 17th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.70.
Cooper Companies Trading Up 0.1%
COO opened at $69.52 on Monday. Cooper Companies has a 1-year low of $65.00 and a 1-year high of $112.38. The stock has a market capitalization of $13.90 billion, a PE ratio of 33.75, a PEG ratio of 1.69 and a beta of 0.98. The company has a current ratio of 2.10, a quick ratio of 1.23 and a debt-to-equity ratio of 0.30. The firm has a 50-day moving average price of $77.09 and a two-hundred day moving average price of $84.73.
Cooper Companies (NASDAQ:COO – Get Free Report) last announced its earnings results on Thursday, May 29th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.93 by $0.03. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $995.12 million. Cooper Companies had a return on equity of 9.60% and a net margin of 10.39%. Cooper Companies’s revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.85 EPS.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of COO. T. Rowe Price Investment Management Inc. raised its holdings in shares of Cooper Companies by 2.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,678,965 shares of the medical device company’s stock valued at $705,928,000 after purchasing an additional 155,233 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Cooper Companies by 3.4% during the 1st quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock worth $436,681,000 after buying an additional 172,485 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cooper Companies by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 4,906,463 shares of the medical device company’s stock worth $449,907,000 after buying an additional 109,907 shares during the period. Goldman Sachs Group Inc. grew its stake in Cooper Companies by 17.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after buying an additional 686,751 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock valued at $415,985,000 after acquiring an additional 574,899 shares during the period. 24.39% of the stock is owned by institutional investors and hedge funds.
Cooper Companies Company Profile
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.
See Also
- Five stocks we like better than Cooper Companies
- Comparing and Trading High PE Ratio Stocks
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- D-Wave Goes International With South Korea Partnership
- Roth IRA Calculator: Calculate Your Potential Returns
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.